Clinical Trials Using Recombinant Interferon Alfa-2b

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Recombinant Interferon Alfa-2b. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

    This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The atezolizumab plus ipilimumab arm (Arm A) will focus primarily on participants with advanced or metastatic non-small cell lung cancer (NSCLC). The atezolizumab plus interferon alfa-2b arm (Arm B), plus pegylated interferon alfa-2a (PEG−interferon alfa-2a, Arm C), and atezolizumab plus PEG-interferon Alfa-2a plus bevacizumab (Arm D) will enroll participants with advanced or metastatic renal cell carcinoma (RCC), metastatic NSCLC and melanoma. The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent and / or metastatic (R / M) head and neck squamous cell carcinoma (HNSCC). Atezolizumab will be administered as intravenous (IV) infusion every 3 weeks (q3w).
    Location: 4 locations

  • Chemoimmunotherapy and Vaccine Therapy in Treating Patients with Recurrent Ovarian Cancer

    This partially randomized phase I / II trial studies the side effects and best dose of recombinant interferon alfa-2b when given together with cisplatin, rintatolimod, and celecoxib and to see how well they work with vaccine therapy in treating patients with ovarian cancer that has come back (recurrent). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Biological therapies, such as recombinant interferon alpha-2b, rintatolimod, and celecoxib, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a persons white blood cells may help the body build an effective immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. Giving cisplatin, recombinant interferon alpha-2b, rintatolimod, celecoxib, and vaccine therapy may be a better treatment for ovarian cancer.
    Location: 2 locations

  • Pembrolizumab and High-Dose Recombinant Interferon Alfa-2b before and after surgery in Treating Patients with Locally / Regionally Advanced or Recurrent Melanoma

    This phase I trial studies the side effects and best dose of pembrolizumab and high-dose recombinant interferon alfa-2b before and after surgery in treating patients with melanoma that has spread to nearby lymph nodes or organs and tissues (locally / regionally) or has returned after a period of improvement (recurrent). Pembrolizumab may block a substance found on the surface of tumor cells called programmed cell death 1 (PD-1) and may help the immune system to kill the cells. Recombinant interferon alfa-2b interferes with the survival of tumor cells and may slow tumor growth. Giving pembrolizumab and recombinant interferon alfa-2b together may kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma

    This phase I trial studies the side effects and best dose of vemurafenib when given together with recombinant interferon alfa-2b in treating patients with stage III-IV melanoma. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma. Giving vemurafenib and IFN alfa-2b may be an effective treatment for melanoma.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod Before Surgery in Treating Patients With Recurrent or Metastatic Colorectal Cancer That Can Be Removed By Surgery

    This randomized phase I / II trial studies the side effects and best dose of recombinant interferon alfa-2b when given together with rintatolimod before surgery and to see how well they work in treating patients with recurrent or metastatic colorectal cancer that can be removed by surgery. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of colorectal cancer.. Biological therapies such as rintatolimod may stimulate the immune system in different ways and stop tumor cells from growing. Giving celecoxib together with recombinant interferon alfa-2b and rintatolimod before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed..
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Recombinant Interferon Alfa-2b or PEG-Interferon Alfa-2b in Treating Patients With Melanoma Undergoing Sentinel Lymph Node Biopsy

    This randomized pilot clinical trial recombinant interferon alfa-2b (IFN a2b) or pegylated interferon alfa-2b (PEG-interferon alfa-2b) in treating patients with melanoma undergoing sentinel lymph node biopsy. Biological therapies, such as recombinant interferon alfa-2b and PEG-interferon alfa-2b may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill tumor cells. It is not yet known whether interferon alfa-2b is more effective than PEG-interferon alfa-2b in treating melanoma.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Natural History of Recombinant Interferon Alfa-2B or Combination Chemotherapy and Rituximab in Treating Patients with Grade I-III Lymphomatoid Granulomatosis

    This clinical trial studies natural history of recombinant interferon alfa-2B or combination chemotherapy and rituximab in treating patients with grade I-III lymphomatoid granulomatosis. Recombinant interferon alfa-2B may kill cancer cells by stimulating white blood cells to kill lymphoid granulomatosis cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, can block the ability of cancer cells to grow and spread. Gathering information over time about patients with lymphomatoid granulomatosis receiving these treatments may help doctors learn more about the disease and find better methods of treatment and on-going care.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Type-1-polarized Dendritic Cell Vaccine, Interferon Alpha-2b, Rintatolimod, and Celecoxib in Treating Patients with Chemo-refractory Metastatic Colorectal Cancer

    This phase II trial studies how well type-1-polarized dendritic cell vaccine, interferon alpha-2b, rintatolimod, and celecoxib work in treating patients with colorectal cancer that does not respond to chemotherapy and has spread to other places in the body. Vaccines, such as type-1-polarized dendritic cell vaccine may help the body build an effective immune response to kill tumor cells. Interferon alpha-2b may improve the body’s natural response to infections and other diseases and interfere with the division of tumor cells and slow tumor growth. Rintatolimod may stimulate the immune system. Celecoxib may reduce pain and swelling. Giving alpha type-1-polarized dendritic cell vaccine, interferon alpha-2b, rintatolimod, and celecoxib may work better in treating patients with colorectal cancer that does not respond to chemotherapy and has spread to other places in the body.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

    This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

    To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
    Location: Roswell Park Cancer Institute, Buffalo, New York